858O Results of KEYNOTE-122: A phase III study of pembrolizumab (pembro) monotherapy vs chemotherapy (chemo) for platinum-pretreated, recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC)
2021; Elsevier BV; Volume: 32; Linguagem: Inglês
10.1016/j.annonc.2021.08.1268
ISSN1569-8041
AutoresAnthony T.�C. Chan, Victor Lee, R-L. Hong, M-J. Ahn, Wan Qin Chong, S-B Kim, Gwo Fuang Ho, Priscilla B. Caguioa, Nuttapong Ngamphaiboon, Gwo Fuang Ho, M.A.S. Abdul Aziz, Quan Sing Ng, C-J. Yen, Nopadol Soparattanapaisarn, K.C. Ngan, S.K. Kho, Ramona F. Swaby, Sanatan Saraf, Joy Yang Ge, L.L. Siu,
Tópico(s)Cancer Immunotherapy and Biomarkers
ResumoTreatment options for R/M NPC are limited. In the phase Ib KEYNOTE-028 trial, pembro showed antitumor activity and manageable safety in a cohort of 27 patients (pts) with R/M NPC. KEYNOTE-122 (NCT02611960) is a multicenter, open-label, randomized phase III study to evaluate the efficacy and safety of pembro monotherapy vs chemo in pts with platinum-pretreated, R/M NPC.
Referência(s)